Deane, Amber E.
Elmore, Joshua S.
Mayes, Taryn L.
Robinson, Skylar
AlZubi, Yasmin
Wakefield, Sarah M.
Trivedi, Madhukar H.
Funding for this research was provided by:
Center for Depression Research and Clinical Care at the University of Texas Southwestern Medical Center
Texas Child Mental Health Care Consortium
Article History
Accepted: 13 May 2024
First Online: 19 June 2024
Declarations
:
: Dr. Trivedi has provided consulting services to Alkermes Inc, Axsome Therapeutics, Biogen MA Inc., Cerebral Inc., Circular Genomics Inc, Compass Pathfinder Limited, GH Research Limited, Heading Health Inc, Janssen, Legion Health Inc, Merck Sharp & Dohme Corp., Mind Medicine (MindMed) Inc, Merck Sharp & Dhome LLC, Naki Health, Ltd., Neurocrine Biosciences Inc, Noema Pharma AG, Orexo US Inc, Otsuka American Pharmaceutical Inc, Otsuka Canada Pharmaceutical Inc, Otsuka Pharmaceutical Development & Commercialization Inc, Praxis Precision Medicines Inc, SAGE Therapeutics, Sparian Biosciences Inc, Takeda Pharmaceutical Company Ltd, WebMD. He sits on the Scientific Advisory Board of Alto Neuroscience Inc, Cerebral Inc., Compass Pathfinder Limited, Heading Health, GreenLight VitalSign6 Inc, Legion Health Inc, Merck Sharp & Dohme Corp, Orexo US Inc, Signant Health. He holds stock in Alto Neuroscience Inc, Cerebral Inc, Circular Genomics Inc, GreenLight VitalSign6 Inc, Legion Health Inc. Additionally, he has received editorial compensation from American Psychiatric Association, and Oxford University Press. Dr. Deane, Mr. Elmore, Ms. Mayes, Dr. Wakefield, Ms. Alzubi, and Ms. Robinson have no declarations to report.
: Not applicable.